NASDAQ · RLAY
Relay Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RLAY: Nov 5, 2026
Relay Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.4. The reported EPS for the same quarter last year was $-0.43.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.40 | $-0.35 | $-0.43 | 5 |
| Dec 2026 | $-0.37 | $-0.31 | $-0.42 | 4 |
| Mar 2027 | $-0.41 | $-0.39 | $-0.43 | 2 |
| Jun 2027 | $-0.42 | $-0.40 | $-0.44 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · RTTNews- Zacks · Sep 24, 11:08 AM EDTCan Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
- Zacks · Sep 3, 10:32 AM EDTCan RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
- The Motley Fool · Sep 2, 1:20 PM EDTRelay Therapeutics CFO Sells 17,717 Shares for $350,000The sale had an approximate value of nearly $350,000.
- Zacks · Aug 18, 3:43 AM EDTThe Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and AbsciAI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
- Zacks · Aug 17, 9:56 AM EDT4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes PharmaRXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
- Zacks · Aug 6, 7:10 PM EDTRelay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue EstimatesRelay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 6:10 PM EDTAkebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue EstimatesAkebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 3, 7:10 AM EDTShionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings EstimatesShionogi & Co. (SGIOY) delivered earnings and revenue surprises of +100.00% and -0.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 10:00 AM EDTRelay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Jul 13, 4:57 AM EDTReturns Matter: NUTX +214%, CORT +145%, GKOS +97% – Were These Biotech Stocks In Your Portfolio?(RTTNews) – Maximizing investment returns requires careful research, informed analysis, and a disciplined approach to decision-making. As Abigail Johnson, Chairman and CEO of Fidelity Investments, aptly said, "Returns matter a lot. It's our capital."
- The Motley Fool · Jun 29, 8:12 PM EDTRelay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past YearThomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share.
- The Motley Fool · May 22, 5:50 PM EDTIs Relay Therapeutics a Buy After Promising Trial Results?Relay had its initial public offering in 2020.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Relay Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.